Artelo Biosciences ARTL

Drug Manufacturers - General, Healthcare

$2.55

+0.00%

Market cap: $1.3M
PE: n/m; a loss over the last year
Forward PE: n/m; not a meaningful number
Price to sales: n/m; not a meaningful number
EV/EBIT: n/m; a loss over the last year
Revenue, 12 months: n/m; not a meaningful number
Net margin: n/m; not a meaningful number
Free cash flow yield: n/m; not a meaningful number

Artelo Biosciences' trailing earnings are negative, so it has no PE.

Charts

Financials

Income statement for ARTL, by quarter
Income statement	Q3 FY23	Q4 FY23	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
R&D	$1.6M+47%	$2.1M+23%	$1.5M+22%	$1.7M+124%	$325K−80%	$2.5M+17%	$1.4M−8%	$1.9M+11%	$1.3M+292%	$893K−64%	$773K−44%	$876K−53%
SG&A	$1M−22%	$1.1M−36%	$1.1M+2%	$827K−20%	$870K−16%	$1.3M+20%	$995K−8%	$1.3M+55%	$1.8M+109%	$1.9M+42%	$1.9M+93%	$1.6M+27%
	−$2.6M+9%	−$3.2M−7%	−$2.6M+13%	−$2.5M+41%	−$1.2M−54%	−$3.8M+18%	−$2.4M−8%	−$3.1M+25%	−$3.1M+159%	−$2.8M−27%	−$2.7M+13%	−$2.5M−21%
Interest expense	$0	$0	n/a	$0	$0	$0	$0	$72K	$111K	$11K	$100K	$6K−92%
Pre-tax income	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	n/a	$0
Net income	−$2.4M+5%	−$3.1M−8%	−$2.5M+15%	−$2.4M+52%	−$1.1M−54%	−$3.8M+23%	−$2.4M−5%	−$3.2M+32%	−$3.1M+176%	−$4.2M+10%	−$3M+25%	−$2.4M−25%
	−$134.46	−$157.14	−$126.36	−$122.04	−$56.70−58%	−$189.00+20%	−$112.95−11%	−$151.74+24%	−$107.19+89%	−$55.89−70%	−$36.00−68%	−$8.01−95%
	18.2K	n/a	19.7K	19.9K	19.9K+10%	20K	21K+6%	21.2K+7%	29.1K+46%	74.5K+272%	82.1K+291%	301.3K+1320%

SG&A: Q1 FY14: 6 months less the 3 months printed beside them.

Operating income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.

Net income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.

EPS, diluted: 12 periods, Q1 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent. Q4 FY23: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'.

Diluted shares: Q1 FY14 and Q1 FY15: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY14 to Q4 FY21: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Artelo Biosciences' size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
ARTLArtelo Biosciences	$1.3M	n/m	n/a	n/m	n/m	n/m
LNAILunai Bioworks	$1.5M	n/m	n/a	n/m	n/m	n/m
GNPXGenprex	$1.5M	n/m	n/a	n/m	n/m	n/m
GOVXGeoVax Labs	$1.5M	n/m	n/a	n/a	−100%	n/a
ONCOOnconetix	$1.7M	n/m	n/a	n/m	n/m	n/m
MTNBMatinas BioPharma	$1.7M	n/m	n/a	n/m	n/m	n/m
PPCBPropanc Biopharma	$1.8M	n/m	n/a	n/m	n/m	n/m
SILOSilo Pharma	$1.9M	n/m	10.5×	34.7×	−25%	n/m
OGENOragenics	$1.9M	n/m	n/a	n/m	n/m	n/m
KAPAKairos Pharma, LTD.	$1.9M	n/m	n/a	n/m	n/m	n/m
VBIOValion Bio	$834.3K	n/m	n/a	n/m	n/m	n/m
Peer median	$1.7M	n/a	10.5×	34.7×	−62%	n/a